Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy of the Use of Bortezomib for the Treatment of Relapsed Leukemia or Positive Minimal Residual Disease

NCT05137860 is registered in ClinicalTrials.gov with Hospital General de Mexico as lead sponsor.

NCT NCT05137860
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05137860 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy of the Use of Bortezomib for the Treatment of Relapsed Leukemia or Positive Minimal Residual Disease
Lead sponsor
Hospital General de Mexico
Phase
Phase 4
Overall status
Unknown status
Start date
December 12, 2021
Completion date
June 23, 2023
Enrollment
56 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia, in relapse, chemotherapeutic toxicity, minimal residual disease